Approval of Two New Prostate Cancer Drugs Gives Patients and Families Hope May 20, 2020 FOR IMMEDIATE RELEASEMEDIA CONTACT:Ilana Ostrin202-657-2249ilana@zerocancer.org Approval of Two New Prostate Cancer Drugs Gives Patients and Families Hope In the span of a week, the FDA permits two new drugs for advanced prostate cancer patients to move to marketWashington, D.C., May 20, 2020 -- It’s a thrill for prostate cancer advocates when a new treatment moves from the research bench to the patient’s bedside. When this occurs, hope ripples across the cancer community. Lightning struck twice this week for the prostate cancer community, as the FDA approved olaparib (LYNPARZA) for patients with metastatic castration-resistant prostate cancer (mCRPC). The news comes only days after the agency approved another drug (Rubraca) that is also targeted to mCRPC patients.“This news gives patients double the hope as we now have more novel solutions for fighting advanced prostate cancer,” Jamie Bearse, ZERO’s CEO, said. “Now patients have the option of another completely new pharmacological treatment, which has greatly improved outcomes for patients in studies. This is a great example of how we can target treatments based on precision medicine results. It’s exciting to think that future similar advancements will continue to develop and progress to battle prostate cancer.”Olaparib is targeted to patients who have deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene mutations and have progressed following prior treatment with a new hormonal agent. LYNPARZA is jointly developed and commercialized by AstraZeneca and MerckFor more on olaparib and its study findings, click here. About ZERO Prostate CancerZERO Prostate Cancer (ZERO) is on a mission to improve and save lives from prostate cancer through advocacy, education, awareness, and support. Formerly known as the National Prostate Cancer Coalition, ZERO was founded in 1996 to stand up for people impacted by prostate cancer. Today, ZERO serves as the nation's leading prostate cancer organization, advancing a future where prostate cancer detection is early, support is unwavering, and care is accessible to all. For over 30 years, ZERO has led the way in prostate cancer advocacy, screenings, and partnerships, successfully unlocking funding toward breakthrough discoveries, treatments, and lifesaving access to care. As the nation’s #1 provider of prostate cancer resources, programs, and services, ZERO has supported millions of people at-risk or diagnosed, and their families. As the voice of the prostate cancer community, ZERO's urgent focus on breaking barriers to survival—by closing gaps in diagnosis, treatment, and care—brings critical attention to those most likely to be impacted by this disease. Learn more at ZEROcancer.org Press Release
FOR IMMEDIATE RELEASEMEDIA CONTACT:Ilana Ostrin202-657-2249ilana@zerocancer.org Approval of Two New Prostate Cancer Drugs Gives Patients and Families Hope In the span of a week, the FDA permits two new drugs for advanced prostate cancer patients to move to marketWashington, D.C., May 20, 2020 -- It’s a thrill for prostate cancer advocates when a new treatment moves from the research bench to the patient’s bedside. When this occurs, hope ripples across the cancer community. Lightning struck twice this week for the prostate cancer community, as the FDA approved olaparib (LYNPARZA) for patients with metastatic castration-resistant prostate cancer (mCRPC). The news comes only days after the agency approved another drug (Rubraca) that is also targeted to mCRPC patients.“This news gives patients double the hope as we now have more novel solutions for fighting advanced prostate cancer,” Jamie Bearse, ZERO’s CEO, said. “Now patients have the option of another completely new pharmacological treatment, which has greatly improved outcomes for patients in studies. This is a great example of how we can target treatments based on precision medicine results. It’s exciting to think that future similar advancements will continue to develop and progress to battle prostate cancer.”Olaparib is targeted to patients who have deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene mutations and have progressed following prior treatment with a new hormonal agent. LYNPARZA is jointly developed and commercialized by AstraZeneca and MerckFor more on olaparib and its study findings, click here.
About ZERO Prostate CancerZERO Prostate Cancer (ZERO) is on a mission to improve and save lives from prostate cancer through advocacy, education, awareness, and support. Formerly known as the National Prostate Cancer Coalition, ZERO was founded in 1996 to stand up for people impacted by prostate cancer. Today, ZERO serves as the nation's leading prostate cancer organization, advancing a future where prostate cancer detection is early, support is unwavering, and care is accessible to all. For over 30 years, ZERO has led the way in prostate cancer advocacy, screenings, and partnerships, successfully unlocking funding toward breakthrough discoveries, treatments, and lifesaving access to care. As the nation’s #1 provider of prostate cancer resources, programs, and services, ZERO has supported millions of people at-risk or diagnosed, and their families. As the voice of the prostate cancer community, ZERO's urgent focus on breaking barriers to survival—by closing gaps in diagnosis, treatment, and care—brings critical attention to those most likely to be impacted by this disease. Learn more at ZEROcancer.org
